ZBH:NYE-Zimmer Biomet Holdings Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 106.28

Change

+0.04 (+0.04)%

Market Cap

USD 21.64B

Volume

1.46M

Analyst Target

USD 149.44
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

-3.25 (-2.75%)

USD 199.88B
MDT Medtronic PLC

-0.50 (-0.56%)

USD 115.58B
STE STERIS plc

-3.30 (-1.37%)

USD 24.14B
SNN Smith & Nephew SNATS Inc

-0.25 (-0.81%)

USD 13.74B
BIO Bio-Rad Laboratories Inc

+6.79 (+2.04%)

USD 9.45B
GMED Globus Medical

+0.25 (+0.36%)

USD 9.39B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 9.26B
PEN Penumbra Inc

+8.52 (+4.55%)

USD 7.77B
GKOS Glaukos Corp

+0.73 (+0.60%)

USD 6.94B
INSP Inspire Medical Systems Inc

+1.69 (+0.82%)

USD 6.08B

ETFs Containing ZBH

CIB0:XETRA VanEck Bionic Engineering.. 6.55 % 0.00 %

-0.29 (-1.75%)

USD 6.36M
CYBG:LSE VanEck Bionic Engineering.. 6.11 % 0.00 %

-0.28 (-1.75%)

N/A
FLV American Century ETF Trus.. 4.29 % 0.00 %

-0.06 (-1.75%)

N/A
WMW 0.00 % 0.75 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.67% 35% F 14% F
Dividend Return 0.39% 11% F 7% C-
Total Return -12.28% 35% F 13% F
Trailing 12 Months  
Capital Gain -11.66% 38% F 14% F
Dividend Return 0.80% 22% F 9% A-
Total Return -10.86% 38% F 13% F
Trailing 5 Years  
Capital Gain -25.17% 33% F 19% F
Dividend Return 3.38% 10% F 10% F
Total Return -21.79% 33% F 15% F
Average Annual (5 Year Horizon)  
Capital Gain -0.92% 39% F 32% F
Dividend Return -0.21% 42% F 24% F
Total Return 0.72% 25% F 16% F
Risk Return Profile  
Volatility (Standard Deviation) 21.72% 82% B 48% F
Risk Adjusted Return -0.94% 42% F 24% F
Market Capitalization 21.64B 90% A- 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector